KEIFERX
Updated 250 days ago
1356 Beverly Rd. Ste 300 Mclean, VA 22101
KeifeRx is an emerging clinical-stage biopharmaceutical company developing novel and optimized, low dose, orally delivered tyrosine kinase inhibitors (TKIs) for the treatment of multiple, high-need neurodegenerative and immune diseases... KeifeRx's clinical pipeline is led by KFRX01 (Nilotinib BE), an optimized re-formulation of nilotinib with improved bioavailability and solubility, being developed for the treatment of early Alzheimer's disease. Additionally, KeifeRx is advancing its TKI formulations in neurodegenerative diseases, including Mild Cognitive Impairment (MCI), and movement disorders, including Lewy Body Dementia (LBD) and Amyotrophic Lateral Sclerosis (ALS). KeifeRx is also developing novel TKIs targeting inflammatory diseases, including mast cell activated syndromes (MCAS), Lyme disease, and Urticaria, as well as neuro-inflammatory conditions that are features of neurodegeneration... KeifeRx is dedicated to improving the treatment of neurodegenerative and immune..